ArticleBritish journal of haematology2025
Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma.
Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma.British journal of haematology · 2025Article
- Long-term complete remission and minimal side effects after CD19/CD22 CAR-T cell cocktail therapy in a living donor with DLBCL: A rare case report.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Baseline risk factors for acute kidney injury (AKI) during chimeric antigen receptor T-cell (CAR-T) therapy are not well described. Hence, we evaluated the incidence and risk factors associated with AKI among patients undergoing CAR-T for relapsed/refractory large B-cell lymphoma. Among 155 patients, 28 (18%) developed AKI with a median time-to-peak creatinine from CAR-T of 9.5 days (range = 3-30). Aetiologies included volume depletion (n = 20, 71%), cytokine release syndrome (n = 5, 18%), nephrotoxins (n = 5, 18%), tumour lysis syndrome (n = 1, 4%) and multifactorial (n = 6, 21%). On univariable analysis, a history of chronic kidney disease (CKD) relative risk (RR 3.5, 95% CI: 1.9-6.6, p < 0.01), receipt of axicabtagene ciloleucel (RR 2.1, 95% CI: 1.1-4.2, p = 0.04), elevated ferritin (RR 3.1, 95% CI: 1.1-8.4, p = 0.03) and serum creatinine level (RR 2.9, 95% CI: 1.4-6.2, p < 0.01) were associated with AKI. On multivariable analysis, a history of CKD adjusted relative risk (aRR 3.5, 95% CI: 1.9-6.4, p < 0.01) and receipt of axicabtagene ciloleucel (aRR 2.1, 95% CI: 1.1-4.0, p = 0.03) retained statistical significance. Four (2.6%) patients required renal replacement therapy during CAR-T. Twenty-five of 28 patients with AKI had renal recovery with a median time to recovery of 14 days (range = 5-85). Of those without renal recovery, two required long-term haemodialysis and one experienced disease progression and died 34 days after CAR-T. Patients with AKI had shorter median PFS (2.4 vs. 6.9 months, p = 0.02) and OS (7.8 vs. 29.7 months, p < 0.01). Additional research is needed to obviate the risk of renal toxicity and improve post-CAR-T outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.